5 Insightful Analyst Questions From Haemonetics’s Q2 Earnings Call

Haemonetics delivered a Q2 performance that surpassed Wall Street’s revenue and adjusted earnings expectations, supported by consistent execution across its business lines. Management attributed the quarter’s results to strong innovation and commercial momentum, particularly in Plasma and Interventional Technologies, where new product rollouts like Persona PLUS and VASCADE MVP XL drove adoption and utilization. CEO Christopher Simon specifically highlighted, "All three of our core platforms contributed to our performance this quarter, demonstrating the breadth of our business and reinforcing the confidence in our ability to deliver sustainable long-term growth." The company’s disciplined approach to portfolio optimization and investments in sales and marketing further supported durable revenue growth.

Is now the time to buy HAE? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Haemonetics’s Q2 Earnings Call

• Anthony Petrone (Mizuho Financial Group) asked about regaining share in Interventional Technologies and the attach rate for VASCADE with pulsed field ablation. CEO Christopher Simon explained that market stabilization, commercial execution, and the MVP XL label expansion drove recent share gains.
• Allen Gong (JPMorgan) questioned gross margin progression for the remainder of the year. CFO James D’Arecca explained that stable SG&A and favorable mix from Persona PLUS should support sequential margin expansion despite external cost pressures.
• Marie Thibault (U.S. Bancorp BTIG) inquired about the timing and adoption curve for Persona PLUS. Simon responded that the rollout is ahead of schedule, with the pace depending on customer contracts but the ability to convert centers rapidly if demand holds.
• David Rescott (Baird) sought clarification on plasma segment restatement and the contributions from Persona PLUS and disposables. Simon detailed how the segment was reclassified and emphasized the combined impact of share gains, strong demand, and Persona PLUS pricing.
• Joseph Stringer (Needham & Company) asked about capital equipment budgeting trends. Simon confirmed there was no evidence of capital budget tightening affecting TEG placements, emphasizing strong clinical use cases and value-based adoption.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the pace and breadth of Persona PLUS adoption across both U.S. and international plasma centers, (2) the progression of VASCADE MVP XL regulatory approvals and launches in key geographies like Japan, and (3) the impact of recurring revenue growth and product mix on operating margins. We will also be watching for updates on new product development and regulatory milestones that could alter Haemonetics’ addressable market.

Haemonetics currently trades at $91.68, up from $83.60 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.